Surio Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series B
- Investors
-
14
Surio Therapeutics General Information
Description
Manufacturer of biotechnology therapeutics intended to develop innovative treatments for metabolic, cardiovascular, and related diseases. The company offers peptide drug discovery, biologic engineering, and translational research capabilities, enabling pharmaceutical companies and healthcare providers to advance targeted therapeutics and improve treatment outcomes.
Contact Information
Website
www.suriothera.comCorporate Office
- 4th Floor, Building 3, Westlake University Science Park
- Number 1 Yunmeng Road, Zhuantang Street, Xihu District
- Hangzhou, Zhejiang 310024
- China
Corporate Office
- 4th Floor, Building 3, Westlake University Science Park
- Number 1 Yunmeng Road, Zhuantang Street, Xihu District
- Hangzhou, Zhejiang 310024
- China
Surio Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series B) | 02-Nov-2026 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series A) | 28-May-2026 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | 14-Oct-2025 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 10-Aug-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 19-Nov-2021 | $843K | Completed | Generating Revenue | ||
| 1. Seed Round | 24-Sep-2019 | $843K | $843K | Completed | Startup |
Surio Therapeutics Patents
Surio Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025036407-A1 | Aldh-activable funtionalized monosaccarides, pharmaceutical compositions, and diagnostic and therapeutic applications | Inactive | 15-Aug-2023 | ||
| AU-2024288440-A1 | Functionalized auristatins, pharmaceutical compositions, and therapeutic applications | Pending | 10-Jul-2023 | ||
| EP-4743118-A1 | Functionalized auristatins, pharmaceutical compositions, and therapeutic applications | Pending | 10-Jul-2023 | ||
| WO-2025011557-A1 | Functionalized auristatins, pharmaceutical compositions, and therapeutic applications | Inactive | 10-Jul-2023 | ||
| US-20260200964-A1 | Monosaccarides, pharmaceutical compositions, and diagnostic and therapeutic applications | Pending | 08-Dec-2022 | C07H15/26 |
Surio Therapeutics Signals
Surio Therapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Capital Science and Technology Development Group | Venture Capital | Minority | ||
| Wuhan Optics Valley Industrial Investment | Growth/Expansion | Minority | ||
| Highlight Capital | Venture Capital | Minority | ||
| Shanghai Songqing Private Equity Fund Management | Growth/Expansion | Minority | ||
| Hangzhou Dongfang Jiafu Asset Management | Venture Capital | Minority |
Surio Therapeutics FAQs
-
When was Surio Therapeutics founded?
Surio Therapeutics was founded in 2019.
-
Where is Surio Therapeutics headquartered?
Surio Therapeutics is headquartered in Hangzhou, China.
-
What is the size of Surio Therapeutics?
Surio Therapeutics has 10 total employees.
-
What industry is Surio Therapeutics in?
Surio Therapeutics’s primary industry is Drug Discovery.
-
Is Surio Therapeutics a private or public company?
Surio Therapeutics is a Private company.
-
What is Surio Therapeutics’s current revenue?
The current revenue for Surio Therapeutics is .
-
How much funding has Surio Therapeutics raised over time?
Surio Therapeutics has raised $843K.
-
Who are Surio Therapeutics’s investors?
Capital Science and Technology Development Group, Wuhan Optics Valley Industrial Investment, Highlight Capital, Shanghai Songqing Private Equity Fund Management, and Hangzhou Dongfang Jiafu Asset Management are 5 of 14 investors who have invested in Surio Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process